👋
Is this profile yours? Take control to keep your details current, set fees, and respond to reviews.
This page is aggregated from public sources.
Claim this profile →
✓ Verified
Trust score 97/100
Accepting new patients
Dr
Dr Milan Anjanappa
Oncology
English
3,550+
Patients seen
5
Years in practice
9
Publications
1
Languages spoken
About
Consultant Clinical Oncologist – Prostate Cancer Specialist
Dr. Milan Anjanappa is a Consultant Clinical Oncologist specialising in the non-surgical treatment of prostate and complex urological cancers. He has over a decade of experience, having qualified as an Oncologist in 2015.
His aim is simple - to provide the highest standard of personalised cancer care while helping patients make confident, informed decisions about their treatment.
He has a busy NHS practice based at Mount Vernon Cancer Centre in London, one of the UK’s leading specialist cancer centres. He sees many complex cases and delivers advanced, personalised treatment using the latest radiotherapy and systemic therapies.
His private practice focuses on comprehensive care for men with prostate cancer, offering expert guidance and modern treatment options, including advanced radiotherapy techniques, hormone therapy, chemotherapy, immunotherapy, and targeted therapies, particularly for complex or challenging cases.
Dr. Anjanappa combines technical expertise
with a strong commitment to patient-centred care, ensuring each treatment plan
is tailored to the individual’s needs and priorities.
Advanced Prostate and Cancer Treatments
Dr Anjanappa specialises in the management of prostate cancer at all stages, from
newly diagnosed early disease through to advanced and recurrent cancer.
He has extensive expertise in state-of-the-art, non-surgical cancer treatments such as
radiotherapy and systemic treatments, including:
· Precision radiotherapy techniques (image-guided, stereotactic, MR-guided)
· Prostate brachytherapy (high-dose-rate and low-dose-rate seeds)
· Systemic therapies such as hormone therapy, chemotherapy,
immunotherapy, and targeted treatments
· Innovative therapies including Lu-PSMA radioligand therapy for advanced prostate cancer
Dr. Anjanappa’s approach allows treatments to be used alone or in combination, tailored to the patient’s individual needs.
He is particularly experienced in treating patients who:
• Are exploring alternatives to surgery
· Have complex or recurrent prostate cancer
• Require advanced radiotherapy techniques
· Are seeking highly individualised treatment planning or a second opinion
His expertise in advanced radiotherapy and targeted therapies ensures cancer is treated as effectively as possible while minimising side effects and preserving quality of life.
Dr Anjanappa is actively involved in clinical research aimed at improving outcomes
for patients with prostate cancer.
He has participated in numerous clinical trials and research studies as both Principal
Investigator and Sub-Investigator.
His research work includes involvement in major prostate cancer trials such as:
• STAR-TRAP
• POINTER-PC
• STAMPEDE 2
These trials don’t just test new treatments; they inform the future standard of care.
The knowledge gained means more patients can receive safer, more effective, and personalised treatment, even if their cancer has returned or spread.
He has published in peer-reviewed medical journals and presented at national and international conferences.
Dr Anjanappa is recognised by colleagues and patients alike for his thoughtful,
thorough and compassionate care.
Patients value his willingness to spend time explaining complex medical information in a
clear and understandable way.
His combination of specialist expertise, advanced treatments and patient-centred
care makes him a trusted choice for men seeking expert treatment for prostate
cancer.
Dr. Milan Anjanappa is a Consultant Clinical Oncologist specialising in the non-surgical treatment of prostate and complex urological cancers. He has over a decade of experience, having qualified as an Oncologist in 2015.
His aim is simple - to provide the highest standard of personalised cancer care while helping patients make confident, informed decisions about their treatment.
He has a busy NHS practice based at Mount Vernon Cancer Centre in London, one of the UK’s leading specialist cancer centres. He sees many complex cases and delivers advanced, personalised treatment using the latest radiotherapy and systemic therapies.
His private practice focuses on comprehensive care for men with prostate cancer, offering expert guidance and modern treatment options, including advanced radiotherapy techniques, hormone therapy, chemotherapy, immunotherapy, and targeted therapies, particularly for complex or challenging cases.
Dr. Anjanappa combines technical expertise
with a strong commitment to patient-centred care, ensuring each treatment plan
is tailored to the individual’s needs and priorities.
Advanced Prostate and Cancer Treatments
Dr Anjanappa specialises in the management of prostate cancer at all stages, from
newly diagnosed early disease through to advanced and recurrent cancer.
He has extensive expertise in state-of-the-art, non-surgical cancer treatments such as
radiotherapy and systemic treatments, including:
· Precision radiotherapy techniques (image-guided, stereotactic, MR-guided)
· Prostate brachytherapy (high-dose-rate and low-dose-rate seeds)
· Systemic therapies such as hormone therapy, chemotherapy,
immunotherapy, and targeted treatments
· Innovative therapies including Lu-PSMA radioligand therapy for advanced prostate cancer
Dr. Anjanappa’s approach allows treatments to be used alone or in combination, tailored to the patient’s individual needs.
He is particularly experienced in treating patients who:
• Are exploring alternatives to surgery
· Have complex or recurrent prostate cancer
• Require advanced radiotherapy techniques
· Are seeking highly individualised treatment planning or a second opinion
His expertise in advanced radiotherapy and targeted therapies ensures cancer is treated as effectively as possible while minimising side effects and preserving quality of life.
Dr Anjanappa is actively involved in clinical research aimed at improving outcomes
for patients with prostate cancer.
He has participated in numerous clinical trials and research studies as both Principal
Investigator and Sub-Investigator.
His research work includes involvement in major prostate cancer trials such as:
• STAR-TRAP
• POINTER-PC
• STAMPEDE 2
These trials don’t just test new treatments; they inform the future standard of care.
The knowledge gained means more patients can receive safer, more effective, and personalised treatment, even if their cancer has returned or spread.
He has published in peer-reviewed medical journals and presented at national and international conferences.
Dr Anjanappa is recognised by colleagues and patients alike for his thoughtful,
thorough and compassionate care.
Patients value his willingness to spend time explaining complex medical information in a
clear and understandable way.
His combination of specialist expertise, advanced treatments and patient-centred
care makes him a trusted choice for men seeking expert treatment for prostate
cancer.
“Evidence-based care tailored to each patient — taking the time to explain options and shared decisions.”
— Dr Milan Anjanappa
Education & training
-
2011–2017 MD · Medicine and Surgery
-
2017–2021 Residency · Oncology
Career & appointments
-
2021-09–2022-08 Junior consultant
Licenses & insurance
Medical licenses
GB — Organización Médica Colegial de España (OMC)
Board certifications
European Board of Oncology
Malpractice insurance:
Allianz Professional · 2,000,000 EUR coverage
· No claims on file
Procedures performed
| Procedure | Code | Lifetime count |
|---|---|---|
| GP consultation | 99213 | 2,868 |
| Annual physical exam | 99395 | 666 |
| Vaccination administration | 90471 | 2,010 |
| Minor procedure (skin) | 17110 | 869 |
Services & pricing
| Service | Duration | Modality | Price |
|---|---|---|---|
| New patient consultation (60m) | 60 min | in_clinic|telemed | 180.00 EUR |
| Follow-up consultation (30m) | 30 min | in_clinic|telemed|phone | 90.00 EUR |
| Vaccination administration | 30 min | in_clinic | 360.00 EUR |
| Minor procedure (skin) | 120 min | in_clinic | 270.00 EUR |
Office, team & in practice
Videos
Research & publications
h-index: 20 · i10: 9
-
Long-term follow-up of Oncology across GB
DOI: 10.2299/euroclin.2026.0 · PMID: 33216555 · cited by 4
-
Validation of clinical scoring in Oncology
DOI: 10.5916/euroclin.2025.1 · PMID: 38525189 · cited by 70
-
Long-term follow-up of Oncology across GB
DOI: 10.9701/euroclin.2024.2 · PMID: 35878092 · cited by 176
Invited talks
- Practical updates in Oncology European Annual Congress (Oncology) · Vienna · 2024 · invited
- Single-centre experience in Oncology National Society Meeting · · 2023 · oral abstract
Awards & memberships
Awards
- 🏆 Top-rated Oncology — · EuroClinics Patient Choice · 2025 · regional
- 🏆 Excellence in Patient Care · National Society · 2024 · national
- 🏆 Young Investigator Award · European Society · 2023 · international
Society memberships
- WONCA Europe — Family Doctors — Member · since 2022
- national college of family doctors — Member · since 2022
- European Union of Medical Specialists (UEMS) — Member · since 2022
Patient reviews
- Bedside Manner
- 5.00
- Knowledge
- 5.00
- Wait Time
- 4.72
- Staff Friendliness
- 4.99
- Ease Of Appointment
- 4.87
- Value For Money
- 4.89
- Would Recommend Pct
- 98
-
★ 5 verified visit
“Very thorough first visit — explained every step. Booking was easy and the staff were welcoming.”
-
★ 5 verified visit
“Took time to listen and reviewed all my previous results. I would absolutely recommend.”
-
★ 4 verified visit
“Professional and knowledgeable. Wait on the day was a bit long, otherwise excellent.”
Articles by this doctor
- Patient education Patient guide to Oncology
- Awareness When should you see a oncology?
For international patients
- Coordinator
- Patient liaison · milan.anjanappa@euroclinics.example
- Accepted intl insurance
- Allianz Worldwide · AXA Global · BUPA Global · Cigna Global
